ERBB2 and breast cancer: Correspondingly, a phase II study exploring the efficacy of cabozantinib, a small molecule, multi-target inhibitor targeting MET, AXL, rearranged during transfection (RET), HER2, and VEGFR, either alone or with trastuzumab, in heavily pretreated breast cancer patients with brain metastasis, yielded only a 13% CBR and a median PFS of 2.4 months for TNBC patients [90].